Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human coronavirus OC43 3C-like protease (3CLpro), also known as the main protease (Mpro) or non-structural protein 5 (nsp5), is an essential enzyme for the replication of hCoV-OC43, a betacoronavirus associated with the common cold and occasionally severe respiratory disease (UniProt P0C6X6). This cysteine protease mediates the site-specific cleavage of viral polyproteins pp1a and pp1ab at 11 distinct sites, releasing functional non-structural proteins that form the viral replication-transcription complex (PubMed: 26001557). Because 3CLpro possesses a unique substrate specificity—cleaving after a glutamine residue—that is not shared by any known human host cell proteases, it is considered a high-priority therapeutic target for antiviral development (PubMed: 32454408). Therapeutic agents such as nirmatrelvir and experimental inhibitors like GC376 target the catalytic cysteine residue (Cys145) within the active site, effectively blocking viral maturation (PubMed: 33106344). While hCoV-OC43 is often used as a surrogate in research for highly pathogenic coronaviruses like SARS-CoV-2, its 3CLpro remains a direct target for treating infections in immunocompromised individuals where OC43 can cause life-threatening pneumonia (PubMed: 35105572). The enzyme functions as a homodimer, and its activity is crucial for the viral life cycle, making it a focus for pan-coronavirus drug discovery efforts. Inhibition of this target prevents the formation of the replication machinery, thereby stopping the production of new viral particles.
Inhibition of the viral cysteine protease activity, preventing the cleavage of polyproteins pp1a and pp1ab into functional non-structural proteins, thereby halting viral replication.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human coronavirus OC43 3C-like protease (3CLpro) (3CLpro).